Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adenovirus p53 Infected DC Vaccine in Breast Cancer
NCT00082641Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Jan 2004
- Primary completion
- May 2009
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Ad.p53-DC vaccine in breast cancer (2 arms), sponsored by University of Nebraska. Primary endpoints: Number of Participants Who Experienced Toxicity to the Vaccine, Percent of Patients With an Immune Response to p53-infected Autologous Dendritic Cells and 1 more. Started Jan 2004; status: completed.
02
Drugs
Ad.p53-DC vaccine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00082641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082641.